RNA-Targeted Therapeutics for Lipid Metabolic Disorders: From Bench to Bedside.

Research (Wash D C) · 2026 · PMC13184955 · PMID 42164756

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Compared with the placebo, the 400-mg dose administered on days 0 and 90 produced a significant reduction in ApoB on day 180 (−14.3%, P = 0.0085), whereas the effects of the 100- and 800-mg doses did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.